VI Partners
VC Fund
Altendorf, Switzerland
VI Partners is a VC fund in Altendorf focused on Health Care and Biotechnology. Healthcare & Technology Venture Capital since 2001
- Total investments:
- 114
- Last investment:
- Lead investor:
- 24%
- Fund size:
- $110M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries VI Partners invests in
Stages VI Partners invests in
Countries VI Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 8 contacts → | |||
Round size
- Series A
- $3.2M–$23M
- Series B
- $3.3M–$41M
- Series C
- $7M–$100M
Investment Focus
Industry
- Health Care 24 (21%)
- Biotechnology 22 (19%)
- Software 13 (11%)
- Medical Device 13 (11%)
- Artificial Intelligence 10 (9%)
Stage
- Series A 31 (27%)
- Series B 15 (13%)
- Series C 14 (12%)
- Seed 13 (11%)
- Venture - Series Unknown 7 (6%)
Country
- Switzerland 42 (37%)
- Germany 9 (8%)
- United States 4 (4%)
- France 2 (2%)
- Israel 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Nicod
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 7 | Find email | |
Arnd Kaltofen
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 18 | Find email | |
Cyrill Osterwalder
Principal
|
Principal | Total investments: 1 | Find email | |
Diego Braguglia
General Partner
|
General Partner | Total investments: 12 | Find email | |
|
Olivier Laplace
Partner
|
Partner | Total investments: 29 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $90M / Venture - Series Unknown / Sep 22, 2026 | ||
| A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M / Venture - Series Unknown / Jul 28, 2026 | ||
| Airspeed is building powerful, intuitive products that help elite revenue teams sell more effectively | $20M / Series A / Jun 04, 2026 | ||
| XO-Life.com is an online destination center. That provides services includes digital treatment monitoring and patient feedback R&D, marketing and sales. That offers services for Patient Insights, information exchange between patients and pharma, treatments and indications. | $4.7M / Venture - Series Unknown / Apr 14, 2026 | ||
| Imagine knowing your customers’ preferences without tedious analyses, complex spreadsheets, or unreliable focus groups. Buynomics’ AI transforms all your readily available data into Virtual Customers that mimic the buying decisions of real consumers with unmatched precision.Use these instant and accurate consumer insights as the single source oftruth to make decisions on prices, promotions, products, trade terms, channel & portfolio mix. Our holistic approach uncovers the links between critical revenue levers and provides fast and reliable recommendations for best results - your key to profitable and sustainable decisions. | $30M / Series B / Mar 20, 2025 | ||
| Unique is a venture-backed B2B SaaS sales intelligence platform, transforming sales by empowering both sales teams and customers. Unique leverages the power of AI to augment sales teams with real-time coaching and insights to close more deals and build better customer partnerships; and to give customers a better, more transparent, informed buyingexperience. | $30M / Series A / Feb 27, 2025 | ||
| Kadoa is an AI-powered no-code platform that allows anyone to build complex data workflows effortlessly. | Seed / Jan 01, 2025 | ||
| Oplit is a production planning platform that provides software and support to help industrials boost operations profitability. | Seed / Nov 26, 2024 | ||
| Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases. | $11.7M / Series A / Oct 08, 2024 | ||
| Almer Technologies is a startup developing compact and lightweight augmented reality (AR) glasses to deliver effortless communication for frontline workers. Almer Technologies provides AR as a service, including hardware as well as software. | $3M / Seed / Sep 18, 2024 | ||
| See all 114 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does VI Partners invest in?
VI Partners invests primarily in Health Care, Biotechnology and Software startups, most often at Series A and Series B stage. Most of the 114 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is VI Partners's check size?
VI Partners typically joins rounds of $3.2M–$23M at Series A, $3.3M–$41M at Series B and $7M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds VI Partners participates in.
How do I contact VI Partners?
Public channels for VI Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at VI Partners?
The team at VI Partners includes Alain Nicod (Co-Founder and Managing Partner), Arnd Kaltofen (Co-Founder and Managing Partner) and Cyrill Osterwalder (Principal), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
